Total trials
94
Active
2
Phase 3
27
Total enrollment
6,903
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dopacell | — | — | — | — | — | 1 | |
| Immunosuppressive Regimen | — | — | — | — | — | 1 | |
| Autologous Cytokine-Induced Killer (CIK) Cells | — | — | — | — | — | 1 |
Next readouts
- 2028-07
- 2028-08-01
Top conditions
- Infertility19
- Polycystic Ovary Syndrome4
- Osteoarthritis4
- Amyotrophic Lateral Sclerosis4
- Ovarian Hyperstimulation Syndrome3
- Infertility, Female3
- Embryo Implantation2
- Female Infertility2
Frequently asked questions about Royan Institute
- How many clinical trials does Royan Institute have on ClinicalTrials.gov?
- Royan Institute is listed as the lead sponsor on 94 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Royan Institute's trials are in Phase 3?
- 27 of Royan Institute's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Royan Institute focus on?
- Royan Institute's most-studied conditions on ClinicalTrials.gov are Infertility, Polycystic Ovary Syndrome, Osteoarthritis, Amyotrophic Lateral Sclerosis, Ovarian Hyperstimulation Syndrome.
- When are Royan Institute's next clinical trial readouts?
- Royan Institute has 2 upcoming primary-completion readouts tracked here; the soonest is “Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection”, expected around 2028-07.